Veradermics Presents Positive VDPHL01 Data From Two Male Pattern Hair Loss Trials

• Veradermics' oral hair-loss treatment VDPHL01 met both co-primary efficacy endpoints in two registration-directed male studies, with statistically significant benefits versus placebo.
• Study 304 showed hair-count gains of up to 36.4 hairs/cm² at six months; 68.7% reported being improved or much improved.
• The male Phase 3 studies reported no treatment-related serious adverse events or adverse events of special interest of cardiac origin.
• Study 302's treatment-extension topline results are expected in the fourth quarter of 2026.
• The female Phase 2/3 study is fully enrolled with 556 participants; initial topline results are expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.